Older patients treated with the diabetes medications known as thiazolidinediones (which include rosiglitazone) had a significantly increased risk of heart attack, congestive heart failure and death, compared with the use of other hypoglycemic drugs, according to a study in the Dec. 12 issue of JAMA. The authors suggest that these results provide further evidence that this class of medication may cause more harm than good.